|
POTENTIAL FOR INCREASED MYELOTOXICITY AND NEPHROTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
NSAIDS CONCURRENT USE MAY CAUSE INCREASED RISK OF HAEMOTOXICITY
|
|
|
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
CLARITHROMYCIN MAY REDUCE ABSORPTION OF THE DRUG
|
MICONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
PARACETAMOL DEVELOPED SEVERE HEPATOTOXICITY
|
TRIMETHOPRIM DECREASES RENAL CLEARANCE OF THE DRUG
|
FLUCONAZOLE INCREASES SERUM PLASMA CONCENTRATION OF THE DRUG
|
AMPHOTERICIN B INCREASES PLASMA CONCENTRATION OF THE DRUG
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
ZIDOVUDINE HEMATOLOGIC TOXICITY IS INCREASED BY THE CYTOTOXIC DRUGS
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
ZIDOVUDINE HEMATOTOXICITY IS INCREASED
|
ZIDOVUDINE HEMATOTOXICITY IS INCREASED
|
ZIDOVUDINE HEMATOTOXICITY IS INCREASED
|
ZIDOVUDINE HEMATOTOXICITY IS INCREASED
|
ZIDOVUDINE HEMATOTOXICITY IS INCREASED
|
ZIDOVUDINE HEMATOTOXICITY IS INCREASED
|
ZIDOVUDINE HEMATOTOXICITY IS INCREASED
|
ZIDOVUDINE HEMATOTOXICITY IS INCREASED
|
ZIDOVUDINE HEMATOTOXICITY IS INCREASED
|
NELFINAVIR MAY CAUSE DECREASED AUC OF ZIDOVUDINE; ROUTINE DOSE MODIFICATION IS NOT WARRANTED
|
CO-ADMINISTRATION HAS RESULTED IN LOW PHENYTOIN LEVELS IN SOME PT. ; A 30% DECREASE IN ORAL ZIDOVUDINE CLEARANCE WAS OBSERVED WITH PHENYTOIN
|
CO-ADMINISTRATION RESULTS IN INCREASED AUC OF ZIDOVUDINE BY 80%-100%; ROUTINE DOSE MODIFICATION OF ZIDOVUDINE IS NOT WARRANTED UNLESS PT. IS EXPERIENCING PRONOUNCED ANEMIA OR OTHER SEVERE SIDE EFFECTS OF ZIDOVUDINE
|
CO-ADMINISTRATION RESULTS IN INCREASED AUC OF ZIDOVUDINE BY 80%-100%; ROUTINE DOSE MODIFICATION OF ZIDOVUDINE IS NOT WARRANTED UNLESS PT. IS EXPERIENCING PRONOUNCED ANEMIA OR OTHER SEVERE SIDE EFFECTS OF ZIDOVUDINE
|
CO-ADMINISTRATION RESULTS IN INCREASED AUC OF ZIDOVUDINE BY 80%-100%; ROUTINE DOSE MODIFICATION OF ZIDOVUDINE IS NOT WARRANTED UNLESS PT. IS EXPERIENCING PRONOUNCED ANEMIA OR OTHER SEVERE SIDE EFFECTS OF ZIDOVUDINE
|